BioCryst Pharma rises after bigger quarterly sales

BioCryst Pharmaceuticals

04/08/2025 12:44

** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 6.3% to $8.45 premarket

** BCRX posts Q2 revenue of $163.4 million, compared with $109.3 million a year ago

** Company maintains its 2025 revenue forecast for its skin disease drug, Orladeyo, to be between $580 million and $600 million

** Sales of Orladeyo for the quarter rose 45% to $156.8 million

** BioCryst plans to retire all remaining term debt after its European business sale closes in early October

** Up to last close, stock up 5.7% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))